22,135,656
Vote Records
28,570
Companies
12,092
Funds
3,981
Managers

Home › Companies › BIOMARIN PHARMACEUTICAL INC. › 2024-2025

BIOMARIN PHARMACEUTICAL INC. 2024-2025 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and BIOMARIN PHARMACEUTICAL INC.’s Form 8-K, filed May 22, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 13Ballot items
  • 554Asset managers, any item
  • 7,346Fund votes
  • May 20, 2025Meeting date

Results at a glance

Meeting of May 20, 2025: 13 items on BIOMARIN PHARMACEUTICAL INC.’s Form 8-K, filed May 22, 2025: 10 elected · 3 approved.

Dissent

No notable dissent.

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore BIOMARIN PHARMACEUTICAL INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by BIOMARIN PHARMACEUTICAL INC.

These tallies are BIOMARIN PHARMACEUTICAL INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 22, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

BIOMARIN PHARMACEUTICAL INC. — official shareholder meeting results, meeting held May 20, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Elizabeth M. Anderson 160,575,3955,338,859261,996 --10,064,270 97%Elected—
Elect Director: Barbara W. Bodem 164,230,2781,033,669912,303 --10,064,270 99.4%Elected—
Elect Director: Athena Countouriotis 163,915,7341,656,229604,287 --10,064,270 99%Elected—
Elect Director: Willard Dere 163,380,0972,536,182259,971 --10,064,270 98%Elected—
Elect Director: Mark J. Enyedy 164,211,4171,412,156552,677 --10,064,270 99.1%Elected—
Elect Director: Alexander Hardy 164,875,0881,051,826249,336 --10,064,270 99.4%Elected—
Elect Director: Maykin Ho 164,039,8261,878,694257,730 --10,064,270 99%Elected—
Elect Director: Robert J. Hombach 163,224,4082,694,927256,915 --10,064,270 98%Elected—
Elect Director: Richard A. Meier 160,566,3215,338,585271,344 --10,064,270 97%Elected—
Elect Director: Timothy P. Walbert 165,166,799662,209347,242 --10,064,270 99.6%Elected—
2. Ratification of the Selection of Independent Registered Public Accounting Firm The ratification of the selection of KPMG LLP as BioMarin's independent registered public accounting firm for the fiscal year ending December 31, 2025, as set forth in the Proxy 168,601,0897,442,009197,422 ---- 96%Approved—
3. Advisory Vote on the Compensation of Named Executive Officers The advisory (non-binding) vote to approve the compensation of BioMarin's named executive officers, as set forth in the Proxy Statement 155,351,65210,227,321597,277 --10,064,270 94%Approved—
4. Approval of an Amendment to the 2017 Equity Incentive Plan The approval of the Plan Amendment 157,280,8647,747,7681,147,618 --10,064,270 95%Approved—

Source: BIOMARIN PHARMACEUTICAL INC., Form 8-K, filed with the SEC on May 22, 2025 — read the filing on EDGAR.

How asset managers voted at the BIOMARIN PHARMACEUTICAL INC. 2024-2025 meeting

554 asset managers disclosed a vote on at least one BIOMARIN PHARMACEUTICAL INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Alexander Hardy

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

99.4% Majority: yes · of votes cast

FOR 99.4%
FOR: 164,875,088AGAINST: 1,051,826
Details: description as filed, official tally, votes by 132 asset managers

Description as filed by funds: Election of Directors: Alexander Hardy

BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Alexander Hardy”): 164,875,088 for, 1,051,826 against, per its Form 8-K filed May 22, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the ten nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner…”
Support: 99.4% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 132 asset managers below reported 89,032,908 for, 6,597 against, 66,717 abstained.

FOR
FOR: 89,032,908AGAINST: 6,597ABSTAIN: 66,717
Largest asset managers voting on “Election of Directors: Alexander Hardy” at BIOMARIN PHARMACEUTICAL INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard32,152,2370 00For
BlackRock12,596,6040 00For
Dodge & Cox11,525,3250 00For
Capital Group8,669,0690 00For
Fidelity3,339,8810 00For
State Street3,100,0000 00For
PRIMECAP Odyssey Funds2,994,3760 00For
Columbia Threadneedle2,813,6210 00For
Charles Schwab1,505,4510 00For
TIAA843,4330 00For
Aberdeen721,5310 00For
First Trust664,9020 00For
Capitol Series Trust547,0000 00For
TOUCHSTONE STRATEGIC TRUST517,5070 00For
Dimensional488,7640 00For
JPMorgan464,9980 00For
American Century447,4630 00For
Equitable381,0700 00For
Jackson National359,4230 00For
NEW ECONOMY FUND289,8810 00For
Empower246,8990 00For
AQR236,4030 00For
Goldman Sachs218,9050 00For
AIG/SunAmerica213,4590 00For
John Hancock191,4430 00For

Showing the 25 largest of 132 asset managers. All 132 are in the interactive database (link above).

Elect Director: Athena Countouriotis

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 163,915,734AGAINST: 1,656,229
Details: description as filed, official tally, votes by 132 asset managers

Description as filed by funds: Election of Directors: Athena Countouriotis

BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Athena Countouriotis”): 163,915,734 for, 1,656,229 against, per its Form 8-K filed May 22, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the ten nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner…”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 132 asset managers below reported 88,999,138 for, 40,367 against, 66,717 abstained.

FOR
FOR: 88,999,138AGAINST: 40,367ABSTAIN: 66,717
Largest asset managers voting on “Election of Directors: Athena Countouriotis” at BIOMARIN PHARMACEUTICAL INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard32,152,2370 00For
BlackRock12,596,6040 00For
Dodge & Cox11,525,3250 00For
Capital Group8,669,0690 00For
Fidelity3,339,8810 00For
State Street3,100,0000 00For
PRIMECAP Odyssey Funds2,994,3760 00For
Columbia Threadneedle2,813,6210 00For
Charles Schwab1,505,4510 00For
TIAA843,4330 00For
Aberdeen721,5310 00For
First Trust664,9020 00For
Capitol Series Trust547,0000 00For
TOUCHSTONE STRATEGIC TRUST517,5070 00For
Dimensional488,7640 00For
JPMorgan464,9980 00For
American Century447,4630 00For
Equitable381,0700 00For
Jackson National359,4230 00For
NEW ECONOMY FUND289,8810 00For
Empower246,8990 00For
AQR236,4030 00For
Goldman Sachs218,9050 00For
AIG/SunAmerica213,4590 00For
John Hancock191,4430 00For

Showing the 25 largest of 132 asset managers. All 132 are in the interactive database (link above).

Elect Director: Barbara W. Bodem

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

99.4% Majority: yes · of votes cast

FOR 99.4%
FOR: 164,230,278AGAINST: 1,033,669
Details: description as filed, official tally, votes by 132 asset managers

Description as filed by funds: Election of Directors: Barbara W. Bodem

BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Barbara W. Bodem”): 164,230,278 for, 1,033,669 against, per its Form 8-K filed May 22, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the ten nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner…”
Support: 99.4% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 132 asset managers below reported 89,004,257 for, 35,248 against, 66,717 abstained.

FOR
FOR: 89,004,257AGAINST: 35,248ABSTAIN: 66,717
Largest asset managers voting on “Election of Directors: Barbara W. Bodem” at BIOMARIN PHARMACEUTICAL INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard32,152,2370 00For
BlackRock12,596,6040 00For
Dodge & Cox11,525,3250 00For
Capital Group8,669,0690 00For
Fidelity3,339,8810 00For
State Street3,100,0000 00For
PRIMECAP Odyssey Funds2,994,3760 00For
Columbia Threadneedle2,813,6210 00For
Charles Schwab1,505,4510 00For
TIAA843,4330 00For
Aberdeen721,5310 00For
First Trust664,9020 00For
Capitol Series Trust547,0000 00For
TOUCHSTONE STRATEGIC TRUST517,5070 00For
Dimensional488,7640 00For
JPMorgan464,9980 00For
American Century447,4630 00For
Equitable381,0700 00For
Jackson National359,4230 00For
NEW ECONOMY FUND289,8810 00For
Empower246,8990 00For
AQR236,4030 00For
Goldman Sachs218,9050 00For
AIG/SunAmerica213,4590 00For
John Hancock191,4430 00For

Showing the 25 largest of 132 asset managers. All 132 are in the interactive database (link above).

Elect Director: Elizabeth M. Anderson

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 5 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 160,575,395AGAINST: 5,338,859
Details: description as filed, official tally, votes by 132 asset managers

Description as filed by funds: Election of Directors: Elizabeth M. Anderson

BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Elizabeth M. Anderson”): 160,575,395 for, 5,338,859 against, per its Form 8-K filed May 22, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the ten nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner…”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 132 asset managers below reported 88,397,404 for, 642,101 against, 66,717 abstained.

FOR
FOR: 88,397,404AGAINST: 642,101ABSTAIN: 66,717
Largest asset managers voting on “Election of Directors: Elizabeth M. Anderson” at BIOMARIN PHARMACEUTICAL INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard32,152,2361 00For
BlackRock12,596,6040 00For
Dodge & Cox11,525,3250 00For
Capital Group8,669,0690 00For
Fidelity3,339,8810 00For
State Street3,100,0000 00For
PRIMECAP Odyssey Funds2,994,3760 00For
Columbia Threadneedle2,813,6210 00For
Charles Schwab1,505,4510 00For
TIAA843,4330 00For
Aberdeen721,5310 00For
First Trust664,9020 00For
Capitol Series Trust547,0000 00For
TOUCHSTONE STRATEGIC TRUST517,5070 00For
Dimensional0488,764 00Against
JPMorgan464,9980 00For
American Century447,4630 00For
Equitable381,0700 00For
Jackson National353,7955,628 00For
NEW ECONOMY FUND289,8810 00For
Empower246,8990 00For
AQR236,4030 00For
Goldman Sachs218,9050 00For
AIG/SunAmerica213,4590 00For
John Hancock110,26981,174 00Mixed

Showing the 25 largest of 132 asset managers. All 132 are in the interactive database (link above).

Elect Director: Mark J. Enyedy

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

99.1% Majority: yes · of votes cast

FOR 99.1%
FOR: 164,211,417AGAINST: 1,412,156
Details: description as filed, official tally, votes by 132 asset managers

Description as filed by funds: Election of Directors: Mark J. Enyedy

BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Mark J. Enyedy”): 164,211,417 for, 1,412,156 against, per its Form 8-K filed May 22, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the ten nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner…”
Support: 99.1% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 132 asset managers below reported 89,004,257 for, 35,248 against, 66,717 abstained.

FOR
FOR: 89,004,257AGAINST: 35,248ABSTAIN: 66,717
Largest asset managers voting on “Election of Directors: Mark J. Enyedy” at BIOMARIN PHARMACEUTICAL INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard32,152,2370 00For
BlackRock12,596,6040 00For
Dodge & Cox11,525,3250 00For
Capital Group8,669,0690 00For
Fidelity3,339,8810 00For
State Street3,100,0000 00For
PRIMECAP Odyssey Funds2,994,3760 00For
Columbia Threadneedle2,813,6210 00For
Charles Schwab1,505,4510 00For
TIAA843,4330 00For
Aberdeen721,5310 00For
First Trust664,9020 00For
Capitol Series Trust547,0000 00For
TOUCHSTONE STRATEGIC TRUST517,5070 00For
Dimensional488,7640 00For
JPMorgan464,9980 00For
American Century447,4630 00For
Equitable381,0700 00For
Jackson National359,4230 00For
NEW ECONOMY FUND289,8810 00For
Empower246,8990 00For
AQR236,4030 00For
Goldman Sachs218,9050 00For
AIG/SunAmerica213,4590 00For
John Hancock191,4430 00For

Showing the 25 largest of 132 asset managers. All 132 are in the interactive database (link above).

Elect Director: Maykin Ho

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 164,039,826AGAINST: 1,878,694
Details: description as filed, official tally, votes by 132 asset managers

Description as filed by funds: Election of Directors: Maykin Ho

BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Maykin Ho”): 164,039,826 for, 1,878,694 against, per its Form 8-K filed May 22, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the ten nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner…”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 132 asset managers below reported 89,014,900 for, 24,605 against, 66,717 abstained.

FOR
FOR: 89,014,900AGAINST: 24,605ABSTAIN: 66,717
Largest asset managers voting on “Election of Directors: Maykin Ho” at BIOMARIN PHARMACEUTICAL INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard32,152,2370 00For
BlackRock12,596,6040 00For
Dodge & Cox11,525,3250 00For
Capital Group8,669,0690 00For
Fidelity3,339,8810 00For
State Street3,100,0000 00For
PRIMECAP Odyssey Funds2,994,3760 00For
Columbia Threadneedle2,813,6210 00For
Charles Schwab1,505,4510 00For
TIAA843,4330 00For
Aberdeen721,5310 00For
First Trust664,9020 00For
Capitol Series Trust547,0000 00For
TOUCHSTONE STRATEGIC TRUST517,5070 00For
Dimensional488,7640 00For
JPMorgan464,9980 00For
American Century447,4630 00For
Equitable381,0700 00For
Jackson National359,4230 00For
NEW ECONOMY FUND289,8810 00For
Empower246,8990 00For
AQR236,4030 00For
Goldman Sachs218,9050 00For
AIG/SunAmerica213,4590 00For
John Hancock191,4430 00For

Showing the 25 largest of 132 asset managers. All 132 are in the interactive database (link above).

Elect Director: Richard A. Meier

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 160,566,321AGAINST: 5,338,585
Details: description as filed, official tally, votes by 132 asset managers

Description as filed by funds: Election of Directors: Richard A. Meier

BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Richard A. Meier”): 160,566,321 for, 5,338,585 against, per its Form 8-K filed May 22, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the ten nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner…”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 132 asset managers below reported 88,022,802 for, 1,016,703 against, 66,717 abstained.

FOR
FOR: 88,022,802AGAINST: 1,016,703ABSTAIN: 66,717
Largest asset managers voting on “Election of Directors: Richard A. Meier” at BIOMARIN PHARMACEUTICAL INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard32,150,4311,806 00For
BlackRock12,596,6040 00For
Dodge & Cox11,525,3250 00For
Capital Group8,669,0690 00For
Fidelity3,339,8810 00For
State Street3,099,90397 00For
PRIMECAP Odyssey Funds2,994,3760 00For
Columbia Threadneedle2,813,6210 00For
Charles Schwab1,505,4510 00For
TIAA0843,433 00Against
Aberdeen721,5310 00For
First Trust664,9020 00For
Capitol Series Trust547,0000 00For
TOUCHSTONE STRATEGIC TRUST517,5070 00For
Dimensional488,7640 00For
JPMorgan464,9980 00For
American Century447,4630 00For
Equitable381,0700 00For
Jackson National359,4230 00For
NEW ECONOMY FUND289,8810 00For
Empower246,8990 00For
AQR236,4030 00For
Goldman Sachs218,9050 00For
AIG/SunAmerica213,4590 00For
John Hancock191,4430 00For

Showing the 25 largest of 132 asset managers. All 132 are in the interactive database (link above).

Elect Director: Robert J. Hombach

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 163,224,408AGAINST: 2,694,927
Details: description as filed, official tally, votes by 132 asset managers

Description as filed by funds: Election of Directors: Robert J. Hombach

BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Robert J. Hombach”): 163,224,408 for, 2,694,927 against, per its Form 8-K filed May 22, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the ten nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner…”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 132 asset managers below reported 88,995,797 for, 43,708 against, 66,717 abstained.

FOR
FOR: 88,995,797AGAINST: 43,708ABSTAIN: 66,717
Largest asset managers voting on “Election of Directors: Robert J. Hombach” at BIOMARIN PHARMACEUTICAL INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard32,152,2370 00For
BlackRock12,596,6040 00For
Dodge & Cox11,525,3250 00For
Capital Group8,669,0690 00For
Fidelity3,339,8810 00For
State Street3,100,0000 00For
PRIMECAP Odyssey Funds2,994,3760 00For
Columbia Threadneedle2,813,6210 00For
Charles Schwab1,505,4510 00For
TIAA843,4330 00For
Aberdeen721,5310 00For
First Trust664,9020 00For
Capitol Series Trust547,0000 00For
TOUCHSTONE STRATEGIC TRUST517,5070 00For
Dimensional488,7640 00For
JPMorgan464,9980 00For
American Century447,4630 00For
Equitable381,0700 00For
Jackson National359,4230 00For
NEW ECONOMY FUND289,8810 00For
Empower246,8990 00For
AQR236,4030 00For
Goldman Sachs218,9050 00For
AIG/SunAmerica213,4590 00For
John Hancock191,4430 00For

Showing the 25 largest of 132 asset managers. All 132 are in the interactive database (link above).

Elect Director: Timothy P. Walbert

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

99.6% Majority: yes · of votes cast

FOR 99.6%
FOR: 165,166,799AGAINST: 662,209
Details: description as filed, official tally, votes by 132 asset managers

Description as filed by funds: Election of Directors: Timothy P. Walbert

BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Timothy P. Walbert”): 165,166,799 for, 662,209 against, per its Form 8-K filed May 22, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the ten nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner…”
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 132 asset managers below reported 89,029,307 for, 10,198 against, 66,717 abstained.

FOR
FOR: 89,029,307AGAINST: 10,198ABSTAIN: 66,717
Largest asset managers voting on “Election of Directors: Timothy P. Walbert” at BIOMARIN PHARMACEUTICAL INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard32,152,2370 00For
BlackRock12,596,6040 00For
Dodge & Cox11,525,3250 00For
Capital Group8,669,0690 00For
Fidelity3,339,8810 00For
State Street3,100,0000 00For
PRIMECAP Odyssey Funds2,994,3760 00For
Columbia Threadneedle2,813,6210 00For
Charles Schwab1,505,4510 00For
TIAA843,4330 00For
Aberdeen721,5310 00For
First Trust664,9020 00For
Capitol Series Trust547,0000 00For
TOUCHSTONE STRATEGIC TRUST517,5070 00For
Dimensional488,7640 00For
JPMorgan464,9980 00For
American Century447,4630 00For
Equitable381,0700 00For
Jackson National359,4230 00For
NEW ECONOMY FUND289,8810 00For
Empower246,8990 00For
AQR236,4030 00For
Goldman Sachs218,9050 00For
AIG/SunAmerica213,4590 00For
John Hancock191,4430 00For

Showing the 25 largest of 132 asset managers. All 132 are in the interactive database (link above).

Elect Director: Willard Dere

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 163,380,097AGAINST: 2,536,182
Details: description as filed, official tally, votes by 132 asset managers

Description as filed by funds: Election of Directors: Willard Dere

BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Willard Dere”): 163,380,097 for, 2,536,182 against, per its Form 8-K filed May 22, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the ten nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner…”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 132 asset managers below reported 88,995,797 for, 43,708 against, 66,717 abstained.

FOR
FOR: 88,995,797AGAINST: 43,708ABSTAIN: 66,717
Largest asset managers voting on “Election of Directors: Willard Dere” at BIOMARIN PHARMACEUTICAL INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard32,152,2370 00For
BlackRock12,596,6040 00For
Dodge & Cox11,525,3250 00For
Capital Group8,669,0690 00For
Fidelity3,339,8810 00For
State Street3,100,0000 00For
PRIMECAP Odyssey Funds2,994,3760 00For
Columbia Threadneedle2,813,6210 00For
Charles Schwab1,505,4510 00For
TIAA843,4330 00For
Aberdeen721,5310 00For
First Trust664,9020 00For
Capitol Series Trust547,0000 00For
TOUCHSTONE STRATEGIC TRUST517,5070 00For
Dimensional488,7640 00For
JPMorgan464,9980 00For
American Century447,4630 00For
Equitable381,0700 00For
Jackson National359,4230 00For
NEW ECONOMY FUND289,8810 00For
Empower246,8990 00For
AQR236,4030 00For
Goldman Sachs218,9050 00For
AIG/SunAmerica213,4590 00For
John Hancock191,4430 00For

Showing the 25 largest of 132 asset managers. All 132 are in the interactive database (link above).

Approval of an Amendment to the 2017 Equity Incentive Plan The approval of the Plan Amendment

Official resultCOMPENSATIONReported outcome: Approved

Combines 6 wordings of this item as funds reported it.

95% Approved · of votes cast

FOR 95%
FOR: 157,280,864AGAINST: 7,747,768
Details: description as filed, official tally, votes by 139 asset managers

Description as filed by funds: To approve an amendment to the Company's 2017 Equity Incentive Plan, as amended.

BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“4. Approval of an Amendment to the 2017 Equity Incentive Plan The approval of the Plan Amendment received the following votes”): 157,280,864 for, 7,747,768 against — passed, per its Form 8-K filed May 22, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Based on the votes set forth above, BioMarin's stockholders approved the Plan Amendment.”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of BIOMARIN PHARMACEUTICAL INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Amend Omnibus Stock Plan” (5 managers, Fund and manager reports combined; may count the same shares twice; no share total shown).

The 139 asset managers below reported 88,045,342 for, 728,548 against, 66,717 abstained.

FOR
FOR: 88,045,342AGAINST: 728,548ABSTAIN: 66,717
Largest asset managers voting on “To approve an amendment to the Company's 2017 Equity Incentive Plan, as amended.” at BIOMARIN PHARMACEUTICAL INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard32,152,2361 00For
BlackRock12,596,6040 00For
Dodge & Cox11,525,3250 00For
Capital Group8,669,0690 00For
Fidelity3,339,8810 00For
State Street3,099,90397 00For
PRIMECAP Odyssey Funds2,994,3760 00For
Columbia Threadneedle2,813,6210 00For
Charles Schwab1,505,4510 00For
TIAA843,4330 00For
Aberdeen721,5310 00For
First Trust664,9020 00For
Capitol Series Trust547,0000 00For
TOUCHSTONE STRATEGIC TRUST517,5070 00For
Dimensional488,7640 00For
JPMorgan464,9980 00For
American Century0447,463 00Against
Equitable381,0700 00For
Jackson National359,4230 00For
NEW ECONOMY FUND289,8810 00For
AQR236,4030 00For
Goldman Sachs218,9050 00For
AIG/SunAmerica213,4590 00For
John Hancock191,4430 00For
Nationwide162,8790 00For

Showing the 25 largest of 139 asset managers. All 139 are in the interactive database (link above).

Advisory Vote on the Compensation of Named Executive Officers The advisory (non-binding) vote to approve the…

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 13 wordings of this item as funds reported it.

94% Approved · of votes cast

FOR 94%
FOR: 155,351,652AGAINST: 10,227,321

Prior year: 93.0% for (May 21, 2024 meeting) ▲ 0.9 pts

Details: description as filed, official tally, votes by 553 asset managers

Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement.

BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“3. Advisory Vote on the Compensation of Named Executive Officers The advisory (non-binding) vote to approve the compensation of BioMarin's named executive officers, as set forth in the Proxy Statement, received the follo”): 155,351,652 for, 10,227,321 against — passed, per its Form 8-K filed May 22, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Based on the votes set forth above, BioMarin's stockholders approved, on an advisory basis, the compensation of BioMarin's named executive officers, as set forth in the Proxy Statement.”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 129 asset managers voting on “To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in t” at BIOMARIN PHARMACEUTICAL INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard32,149,7932,444 00For
BlackRock12,596,6040 00For
Dodge & Cox11,525,3250 00For
Capital Group8,669,0690 00For
Fidelity3,339,8810 00For
State Street3,097,6892,311 00For
PRIMECAP Odyssey Funds2,994,3760 00For
Columbia Threadneedle2,813,6210 00For
Charles Schwab1,505,4510 00For
TIAA0843,433 00Against
Aberdeen721,5310 00For
First Trust664,9020 00For
Capitol Series Trust547,0000 00For
TOUCHSTONE STRATEGIC TRUST517,5070 00For
Dimensional488,7640 00For
JPMorgan464,9980 00For
American Century447,4630 00For
Equitable381,0700 00For
Jackson National359,4230 00For
NEW ECONOMY FUND289,8810 00For
Empower246,8990 00For
AQR236,4030 00For
Goldman Sachs218,9050 00For
AIG/SunAmerica213,4590 00For
John Hancock191,4430 00For

Fund voting reports, all 129 managers: 87,889,268 for, 1,107,142 against, 66,717 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 462 asset managers voting on “To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in t” at BIOMARIN PHARMACEUTICAL INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
PRIMECAP MANAGEMENT CO/CA/17,067,6080 00For
Dodge & Cox14,172,8330 00For
VIKING GLOBAL INVESTORS LP10,588,1630 00For
Capital Research Global Investors9,147,5550 00For
BlackRock8,919,92816,657 00For
State Street7,749,96874,178 00For
GEODE CAPITAL MANAGEMENT, LLC3,364,0500 00For
Charles Schwab1,620,3340 00For
Northern Trust1,371,30416,832 00For
AQR1,328,2330 00For
MELLON INVESTMENTS Corp1,239,2650 00For
Palo Alto Investors LP1,136,2240 00For
JPMorgan1,093,6990 00For
Soleus Capital Management, L.P.1,089,3040 00For
AMERIPRISE FINANCIAL INC1,062,0670 00For
DnB Asset Management AS1,001,6750 00For
Nuveen0953,511 00Against
Goldman Sachs801,7970 00For
FULLER & THALER ASSET MANAGEMENT, INC.798,6990 00For
Vanguard759,4410 00For
Aberdeen751,1470 00For
FORT WASHINGTON INVESTMENT ADVISORS INC /OH/647,2170 00For
CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM0623,928 00Against
Citadel616,5500 00For
Candriam S.C.A.0607,862 00Against

Institutional-manager reports, all 462 managers: 103,871,557 for, 7,626,985 against, 453,532 abstained, 4,165 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of the Selection of Independent Registered Public Accounting Firm The ratification of the selection of…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

96% Approved · of votes cast

FOR 96%
FOR: 168,601,089AGAINST: 7,442,009

Prior year: 96.1% for (May 21, 2024 meeting) ▼ 0.3 pts

Details: description as filed, official tally, votes by 131 asset managers

Description as filed by funds: To ratify the selection of KPMG LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2025.

BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“2. Ratification of the Selection of Independent Registered Public Accounting Firm The ratification of the selection of KPMG LLP as BioMarin's independent registered public accounting firm for the fiscal year ending Decem”): 168,601,089 for, 7,442,009 against — passed, per its Form 8-K filed May 22, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Based on the votes set forth above, BioMarin's stockholders ratified the selection of KPMG LLP as BioMarin's independent registered public accounting firm to serve for the year ending December 31, 2025.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of BIOMARIN PHARMACEUTICAL INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Ratify Appointment of Independent Auditors” (2 managers, 1,350 for, 30,169 against).

The 131 asset managers below reported 88,973,828 for, 35,508 against, 66,717 abstained.

FOR
FOR: 88,973,828AGAINST: 35,508ABSTAIN: 66,717
Largest asset managers voting on “To ratify the selection of KPMG LLP as the independent registered public accounting firm for the Company for t” at BIOMARIN PHARMACEUTICAL INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard32,150,4301,807 00For
BlackRock12,596,6040 00For
Dodge & Cox11,525,3250 00For
Capital Group8,669,0690 00For
Fidelity3,339,8810 00For
State Street3,099,809191 00For
PRIMECAP Odyssey Funds2,994,3760 00For
Columbia Threadneedle2,813,6210 00For
Charles Schwab1,505,4510 00For
TIAA843,4330 00For
Aberdeen721,5310 00For
First Trust664,9020 00For
Capitol Series Trust547,0000 00For
TOUCHSTONE STRATEGIC TRUST517,5070 00For
Dimensional488,7640 00For
JPMorgan464,9980 00For
American Century447,4630 00For
Equitable381,0700 00For
Jackson National359,4230 00For
NEW ECONOMY FUND289,8810 00For
Empower246,8990 00For
AQR236,4030 00For
Goldman Sachs218,9050 00For
AIG/SunAmerica213,4590 00For
John Hancock191,4430 00For

Showing the 25 largest of 131 asset managers. All 131 are in the interactive database (link above).

Largest BIOMARIN PHARMACEUTICAL INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 191,755,802 shares outstanding at the time of that meeting.

Fund voting reports: top BIOMARIN PHARMACEUTICAL INC. shareholders by shares voted on “To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as…”, 2024-2025
#Asset manager % of shares outstanding
1Vanguard 16.77%
2BlackRock 6.57%
3Dodge & Cox 6.01%
4Capital Group 4.52%
5Fidelity 1.74%
6State Street 1.62%
7PRIMECAP Odyssey Funds 1.56%
8Columbia Threadneedle 1.47%
9Charles Schwab 0.79%
10TIAA 0.44%
Institutional-manager reports: top BIOMARIN PHARMACEUTICAL INC. shareholders by shares voted on “To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as…”, 2024-2025
#Asset manager % of shares outstanding
1PRIMECAP MANAGEMENT CO/CA/ 8.90%
2Dodge & Cox 7.39%
3VIKING GLOBAL INVESTORS LP 5.52%
4Capital Research Global Investors 4.77%
5BlackRock 4.66%
6State Street 4.08%
7GEODE CAPITAL MANAGEMENT, LLC 1.75%
8Charles Schwab 0.85%
9Northern Trust 0.72%
10AQR 0.69%

Reported BIOMARIN PHARMACEUTICAL INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

BIOMARIN PHARMACEUTICAL INC. holdings and ownership disclosed for the 2024-2025 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
The Vanguard Group18,992,533 9.90%Proxy statement (DEF 14A), proxy filed April 8, 2025
BlackRock, Inc.17,560,751 9.16%Schedule 13G, filed January 21, 2026
PRIMECAP MANAGEMENT CO/CA/15,795,383 8.24%Schedule 13G, filed August 14, 2025
Dodge & Cox13,994,063 7.30%Proxy statement (DEF 14A), proxy filed April 8, 2025
Vanguard Capital Management10,113,219 5.27%Schedule 13G, filed April 29, 2026
Entities affiliated with Viking Global Investors LP9,753,293 5.09%Proxy statement (DEF 14A), proxy filed April 8, 2025
Capital Research Global Investors9,150,655 4.77%Schedule 13G, filed May 13, 2025
State Street8,463,090 4.41%Form 13F, quarter ended March 31, 2025
VIKING GLOBAL INVESTORS LP8,322,179 4.34%Schedule 13G, filed November 14, 2025
Norges Bank3,478,512 1.81%Form 13F, quarter ended March 31, 2025

Percentages above are of 191,755,802 shares outstanding, as reported by BIOMARIN PHARMACEUTICAL INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At BIOMARIN PHARMACEUTICAL INC.'s shareholder meeting held May 20, 2025, in the 2024-2025 proxy season, 554 asset managers reported votes on at least one of its 13 ballot items in their SEC Form N-PX filings, covering 7,346 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as… — BIOMARIN PHARMACEUTICAL INC.'s filing reports the proposal as approved, with 94% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: BIOMARIN PHARMACEUTICAL INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 22, 2025.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from BIOMARIN PHARMACEUTICAL INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

BIOMARIN PHARMACEUTICAL INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Cite this page

Proxy Votes Now, “BIOMARIN PHARMACEUTICAL (BMRN) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/biomarin-pharmaceutical-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.